Related Experiment Videos
Immunity elicited by hepatitis C virus
P Farci1, G Orgiana, R H Purcell
1Istituto di Medicina Interna, Università di Cagliari, Italy.
Insights
Hepatitis C virus (HCV) infection often fails to induce protective immunity, hindering vaccine development. Its genetic diversity presents a significant challenge for creating a broadly effective HCV vaccine.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Hepatitis C virus (HCV) is a global health concern, causing chronic liver disease and liver cancer.
- HCV exhibits significant genetic heterogeneity, complicating infection control and vaccine strategies.
Purpose of the Study:
- To evaluate the host immune response to Hepatitis C virus (HCV) infection.
- To assess the potential for developing a broadly protective HCV vaccine.
Main Methods:
- Review of clinical observations in patients and experimental data from chimpanzee models.
- Analysis of in vitro and in vivo studies on HCV-induced antibody responses.
Main Results:
- Most HCV infections lead to chronic disease, indicating immune system failure to clear the virus.
- Studies show convalescent chimpanzees and re-infected children lack protection against homologous and heterologous HCV strains.
- While neutralizing antibodies are produced, they are isolate-specific and ineffective against evolving viral variants.
Conclusions:
- HCV infection generally does not elicit a lasting protective immune response.
- The genetic diversity of HCV is a primary obstacle to developing a broadly effective vaccine.
- Further research is needed to overcome HCV's heterogeneity for successful vaccination strategies.
Abstract:
Hepatitis C virus (HCV), the major causative agent of post-transfusion and community-acquired non-A, non-B (NANB), is a single-stranded RNA virus characterized by a high degree of genetic heterogeneity. HCV is endemic worldwide and is a major cause of chronic liver disease and hepatocellular carcinoma. The development of a broadly reactive vaccine is a high priority for the control of HCV infection. In recent years, however, serious concerns have been raised regarding the degree of protective immunity elicited by HCV in the host. Several observations, both in patients and in the chimpanzee model, have suggested a lack of protective immunity against HCV. Chronic HCV infection develops in more than 80% of patients, suggesting that in most cases the immune response of the host fails to mediate resolution of the infection. Cross-challenge studies demonstrated that convalescent chimpanzees are not protected against re-infection with homologous or heterologous HCV strains. Similar evidence has been obtained in polytransfused beta-thalassemic children, in whom re-infection with HCV was associated with multiple episodes of acute hepatitis. Although most of the evidence thus far accumulated suggests that HCV does not elicit a protective immune response, recent studies have provided experimental evidence, both in vitro and in vivo, that HCV infection induces a neutralizing antibody response in humans. However, such antibodies are isolate-restricted and ineffective against variant HCV strains emerging in vivo. Recently, using recombinant envelope proteins of HCV, a successful vaccination of chimpanzees against challenge with a homologous viral strain was reported. Whether this vaccine can provide protection against challenge with a higher infectious dose of the homologous virus or against challenge with heterologous strains of HCV remains to be established. Overall, the data hitherto accumulated indicate that the genetic heterogeneity of HCV will be a major impediment for the development of a broadly reactive vaccine for the control of HCV infection.